Unit of Molecular Biology and Nutrigenomics, School of Pharmacy, University of Camerino, Camerino, Italy.
School of Advanced Studies, University of Camerino, Camerino, Italy.
FASEB J. 2021 Jul;35(7):e21694. doi: 10.1096/fj.202100056R.
Among cardiovascular disease (CVD) biomarkers, the mitochondrial DNA copy number (mtDNAcn) is a promising candidate. A growing attention has been also dedicated to trimethylamine-N-oxide (TMAO), an oxidative derivative of the gut metabolite trimethylamine (TMA). With the aim to identify biomarkers predictive of CVD, we investigated TMA, TMAO, and mtDNAcn in a population of 389 coronary artery disease (CAD) patients and 151 healthy controls, in association with established risk factors for CVD (sex, age, hypertension, smoking, diabetes, glomerular filtration rate [GFR]) and troponin, an established marker of CAD. MtDNAcn was significantly lower in CAD patients; it correlates with GFR and TMA, but not with TMAO. A biomarker including mtDNAcn, sex, and hypertension (but neither TMA nor TMAO) emerged as a good predictor of CAD. Our findings support the mtDNAcn as a promising plastic biomarker, useful to monitor the exposure to risk factors and the efficacy of preventive interventions for a personalized CAD risk reduction.
在心血管疾病 (CVD) 生物标志物中,线粒体 DNA 拷贝数 (mtDNAcn) 是一个很有前途的候选物。人们也越来越关注肠道代谢物三甲胺 (TMA) 的氧化衍生物氧化三甲胺 (TMAO)。为了确定预测 CVD 的生物标志物,我们在 389 名冠心病 (CAD) 患者和 151 名健康对照者中研究了 TMA、TMAO 和 mtDNAcn,并与 CVD 的既定危险因素(性别、年龄、高血压、吸烟、糖尿病、肾小球滤过率 [GFR])和 Troponin(CAD 的既定标志物)相关联。CAD 患者的 mtDNAcn 明显降低;它与 GFR 和 TMA 相关,但与 TMAO 无关。包括 mtDNAcn、性别和高血压(而非 TMA 或 TMAO)在内的生物标志物被证明是 CAD 的良好预测因子。我们的研究结果支持 mtDNAcn 作为一种有前途的可塑性生物标志物,可用于监测暴露于危险因素和预防干预措施对 CAD 风险降低的效果。